Kadowaki J
Department of Pediatrics, National Nishi-Sapporo Hospital, Japan.
Hokkaido Igaku Zasshi. 1994 May;69(3):403-10.
The glucocorticoid treatment of patients with idiopathic nephrotic syndrome in children was reported especially focused upon the dose of initial treatment and different effect of various glucocorticoids if they were used equivalently. It appeared that lower dose prednisolone; 40 mg/m2 bsa (body surface area) was also effective same as 60 mg/m2 bsa of protocol of ISKDC (International Study of Kidney Disease in Children) for the initial treatment if time for free proteinuria was taken as index. Therefore, it was considered favorable that we could use lower dose to avoid various adverse effects of glucocorticoids. Clinically it was felt that some different effects were present despite of their equivalent use. The equivalency of various glucocorticoids was based upon anti-inflammatory effect experimentally. The etiology of idiopathic nephrotic syndrome has not been well known, however some sort of immune disorder has been thought most important. Therefore, it might be acceptable if effect of glucocorticoid treatment of nephrotic syndrome is evaluated on the basis of immunosuppression. It is hoped that these empirically proven evidence should be analysed fundamentally in the near future.
据报道,儿童特发性肾病综合征患者的糖皮质激素治疗特别关注初始治疗剂量以及各种糖皮质激素等效使用时的不同效果。如果以无蛋白尿时间为指标,似乎初始治疗时,40mg/m²体表面积的低剂量泼尼松龙与国际儿童肾脏病研究(ISKDC)方案中60mg/m²体表面积的效果相同。因此,认为使用较低剂量以避免糖皮质激素的各种不良反应是有利的。临床上感觉,尽管等效使用,但仍存在一些不同的效果。各种糖皮质激素的等效性是基于实验性抗炎作用。特发性肾病综合征的病因尚不清楚,然而某种免疫紊乱被认为是最重要的。因此,如果基于免疫抑制来评估糖皮质激素治疗肾病综合征的效果,可能是可以接受的。希望这些经验证的证据在不久的将来能得到根本性分析。